{"id":"anti-integrin-vedolizumab-iv","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Nasopharyngitis"},{"rate":"8–12","effect":"Headache"},{"rate":"5–10","effect":"Arthralgia"},{"rate":"5–8","effect":"Nausea"},{"rate":"3–5","effect":"Pyrexia"},{"rate":"1–3","effect":"Infections (serious)"}]},"_chembl":{"chemblId":"CHEMBL1743087","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vedolizumab binds to α4β7 integrin, an adhesion molecule expressed on gut-homing lymphocytes, and prevents these cells from adhering to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the intestinal vasculature. This selective gut-targeting mechanism reduces immune cell infiltration into the bowel while sparing systemic immunity, thereby decreasing intestinal inflammation in inflammatory bowel disease.","oneSentence":"Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on immune cells, preventing their migration to the gut and reducing intestinal inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:01.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe ulcerative colitis"},{"name":"Moderate to severe Crohn's disease"}]},"trialDetails":[{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":"Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8","enrollment":800},{"nctId":"NCT04407247","phase":"PHASE1, PHASE2","title":"Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-09","conditions":"Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm","enrollment":47},{"nctId":"NCT06815003","phase":"PHASE2","title":"Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-04-18","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":35},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT02834754","phase":"PHASE2","title":"Vedolizumab Post Op Study","status":"WITHDRAWN","sponsor":"Marc Schwartz","startDate":"2018-12-01","conditions":"Crohn's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anti-integrin - Vedolizumab IV","genericName":"Anti-integrin - Vedolizumab IV","companyName":"University of Calgary","companyId":"university-of-calgary","modality":"Biologic","firstApprovalDate":"","aiSummary":"Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on immune cells, preventing their migration to the gut and reducing intestinal inflammation. Used for Moderate to severe ulcerative colitis, Moderate to severe Crohn's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}